Summit Therapeutics Past Earnings Performance
Past criteria checks 0/6
Summit Therapeutics's earnings have been declining at an average annual rate of -70.9%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 85% per year.
Key information
-70.9%
Earnings growth rate
-21.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -85.0% |
Return on equity | -791.5% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress
Jan 30We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely
Dec 29Summit Therapeutics slips on plans to terminate study for lead candidate
Oct 04Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio
Aug 17Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M
Aug 11Summit to explore additional trial for its bacteria-induced colon infection drug
Jul 14Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation
Apr 29Summit Therapeutics - Disappointing Data But Not An Outright Failure
Dec 23Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator
Jun 22Summit Therapeutics to join Russell 3000 Index
Jun 08Revenue & Expenses BreakdownBeta
How Summit Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -615 | 30 | 59 |
30 Sep 23 | 0 | -598 | 26 | 41 |
30 Jun 23 | 0 | -598 | 26 | 43 |
31 Mar 23 | 0 | -600 | 27 | 43 |
31 Dec 22 | 1 | -79 | 27 | 53 |
30 Sep 22 | 1 | -87 | 27 | 70 |
30 Jun 22 | 2 | -85 | 27 | 73 |
31 Mar 22 | 2 | -93 | 26 | 88 |
31 Dec 21 | 2 | -89 | 24 | 85 |
30 Sep 21 | 2 | -75 | 19 | 75 |
30 Jun 21 | 1 | -73 | 20 | 69 |
31 Mar 21 | 1 | -64 | 20 | 59 |
31 Dec 20 | 1 | -53 | 19 | 53 |
30 Sep 20 | 1 | -51 | 21 | 51 |
30 Jun 20 | 1 | -40 | 16 | 47 |
31 Mar 20 | -5 | -31 | 13 | 46 |
31 Dec 19 | 1 | -32 | 12 | 43 |
31 Oct 19 | 26 | -28 | 12 | 44 |
31 Jul 19 | 24 | -27 | 12 | 43 |
30 Apr 19 | 72 | 12 | 14 | 47 |
31 Jan 19 | 57 | 11 | 17 | 52 |
31 Oct 18 | 70 | 2 | 18 | 51 |
31 Jul 18 | 72 | 11 | 15 | 51 |
30 Apr 18 | 27 | -29 | 16 | 49 |
31 Jan 18 | 20 | -29 | 17 | 41 |
31 Oct 17 | 15 | -18 | 13 | 32 |
31 Jul 17 | 12 | -23 | 13 | 27 |
30 Apr 17 | 5 | -27 | 12 | 25 |
31 Jan 17 | 3 | -27 | 10 | 24 |
31 Oct 16 | 1 | -29 | 8 | 23 |
31 Jul 16 | 1 | -33 | 8 | 26 |
30 Apr 16 | 1 | -32 | 8 | 27 |
31 Jan 16 | 2 | -29 | 7 | 24 |
31 Oct 15 | 2 | -25 | 7 | 23 |
31 Jul 15 | 3 | -20 | 6 | 20 |
30 Apr 15 | 3 | -19 | 7 | 17 |
31 Jan 15 | 3 | -17 | 6 | 16 |
31 Oct 14 | 3 | -17 | 6 | 16 |
31 Jul 14 | 4 | -17 | 6 | 16 |
30 Apr 14 | 4 | -13 | 4 | 14 |
31 Jan 14 | 3 | -10 | 3 | 11 |
31 Oct 13 | 0 | -8 | 3 | 9 |
31 Jul 13 | 2 | -6 | 3 | 6 |
30 Apr 13 | 2 | -7 | 3 | 6 |
Quality Earnings: SMMT is currently unprofitable.
Growing Profit Margin: SMMT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SMMT is unprofitable, and losses have increased over the past 5 years at a rate of 70.9% per year.
Accelerating Growth: Unable to compare SMMT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SMMT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: SMMT has a negative Return on Equity (-791.49%), as it is currently unprofitable.